Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07220577 · ClinicalTrials.gov registry record · Phase 2

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
84
Enrollment target
20
Study locations

NCT07220577 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 84 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07220577, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
84 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).

Conditions Studied

Atopic Dermatitis

Interventions

  • OTHER Placebo
  • DRUG GIA632

Study Locations (20)

Other

  • Novartis Investigative Site - Pleven
  • Novartis Investigative Site - Sofia
  • Novartis Investigative Site - Sofia
  • Novartis Investigative Site - Prague
  • Novartis Investigative Site - Antony
  • Novartis Investigative Site - Dijon
  • Novartis Investigative Site - Martigues
  • Novartis Investigative Site - Nice
  • Novartis Investigative Site - Berlin
  • Novartis Investigative Site - Hamburg
  • Novartis Investigative Site - Mainz
  • Novartis Investigative Site - Kuala Lumpur

California

  • Ctr for Dermatology Clinical Res - Fremont

Maryland

  • Aesthetics Skin Care Dermatologic Surgery - Rockville

New Jersey

  • Care Access Hoboken - Hoboken

Ontario

  • Novartis Investigative Site - Toronto

Quebec

  • Novartis Investigative Site - Québec

Poruba

  • Novartis Investigative Site - Ostrava

Perak

  • Novartis Investigative Site - Ipoh

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2025-11-10
Est. Completion 2027-09-06
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07220577

The ClinicalTrials.gov registry entry for NCT07220577 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (86% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07220577 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT07220577 about?

NCT07220577 is a clinical study titled "Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis". The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).

What is the current status of trial NCT07220577?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2025-11-10. Estimated completion is 2027-09-06.

What conditions does trial NCT07220577 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT07220577?

The interventions under investigation include: Placebo (OTHER), GIA632 (DRUG).

Who is sponsoring clinical trial NCT07220577?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07220577 being conducted?

This trial has 20 study locations across California, Maryland, New Jersey, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.